粪便免疫化学检测结直肠癌筛查中的风险适配截断值
在4332名筛查结肠镜受试者中,按风险评分三分位分为低、中、高风险组,评估固定和风险适配的粪便免疫化学检测截断值下进展期肿瘤的阳性预测值和需结肠镜数。固定截断值10 μg/g时,阳性预测值从低危组23.3%升至高危组41.8%,需结肠镜数从4.3降至2.4(P<0.001)。使用风险适配截断值可能有助于达到目标阳性预测值和需结肠镜数。
要点
- 固定截断值10 μg/g时,低危组阳性预测值23.3%,高危组41.8%。
- 固定截断值10 μg/g时,低危组需结肠镜数4.3,高危组2.4(P<0.001)。
- 风险适配截断值可能有助于达到目标阳性预测值和需结肠镜数。
核心结论
- 使用风险适配截断值可能有助于达到目标水平的阳性预测值和需结肠镜数,或可作为个性化粪便免疫化学检测结直肠癌筛查的考虑选项。
研究设计与样本
- 在4332名筛查结肠镜受试者中,于肠道准备前采集粪便样本进行定量粪便免疫化学检测(FOB Gold;Sentinel Diagnostics,米兰,意大利)。
- 受试者按先前推导的风险因素评分三分位分为低、中、高3个风险组。
主要发现
- 固定粪便免疫化学检测截断值10 μg/g时,阳性预测值从低危组23.3%升至高危组41.8%,需结肠镜数从4.3降至2.4(P<0.001)。
- 在更高粪便免疫化学检测截断值下,各风险组间阳性预测值和需结肠镜数观察到类似变化。
- 为在所有风险组达到固定阳性预测值25%、30%和35%,高危组与低危组之间的截断值分别变化于5.3至11.4、6.5至18.7和7.5至31.0 μg血红蛋白/g粪便(所有差异P<0.05)。
临床怎么用
- 作者认为,使用风险适配截断值可能有助于达到目标水平的阳性预测值和需结肠镜数,或可作为个性化粪便免疫化学检测结直肠癌筛查的考虑选项。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Fecal immunochemical tests (FITs) for hemoglobin are increasingly used in colorectal cancer (CRC) screening. The use of uniform positivity thresholds (cutoffs) within screening populations is expected to imply lower positive predictive values (PPVs) and higher numbers of colonoscopies needed (numbers needed to scope [NNSs]) to detect advanced neoplasms among screening participants at lower risk compared with those at higher risk. We aimed to assess such variation and its potential implications in a large screening cohort. METHODS: A quantitative FIT (FOB Gold; Sentinel Diagnostics, Milan, Italy) was conducted in fecal samples collected by 4,332 participants of screening colonoscopy before bowel preparation. Participants were classified into 3 risk groups (low, medium, and high) by tertiles of a previously derived risk-factor-based risk score. We determined the variation of PPVs and NNSs for detecting advanced neoplasms (i.e., CRC or advanced adenoma) when using the same FIT cutoffs and variation of FIT cutoffs that would yield uniform PPVs across risk groups. RESULTS: When a fixed FIT cutoff of 10 μg/g was used, the PPV increased from 23.3% to 41.8% from the low- to the high-risk group, with NNS decreasing from 4.3 to 2.4 (P < 0.001). Similar variations of PPVs and NNSs across risk groups were observed at higher FIT cutoffs. When risk group-specific cutoffs were defined to achieve fixed PPVs of 25%, 30%, and 35% across all risk groups, cutoffs varied from 5.3 to 11.4, 6.5 to 18.7, and 7.5 to 31.0 μg hemoglobin/g feces, respectively, between high- and low-risk groups (P < 0.05 for all differences). DISCUSSION: Using risk-adapted cutoffs may help to achieve target levels of PPV and NNS and might be an option to consider for personalized FIT-based CRC screening.
引用
- Peng L, Balavarca Y, Niedermaier T, et al. Risk-Adapted Cutoffs in Colorectal Cancer Screening by Fecal Immunochemical Tests. Am J Gastroenterol. 2020. PMID: 32618662. doi:10.14309/ajg.0000000000000579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。